Clinical Review of Proton Therapy in the Treatment of Unilateral Head and Neck Cancers

Robert H. Press, MD1; Richard L. Bakst, MD2; Sonam Sharma, MD2; Rafi Kabarriti, MD3; Madhur K. Garg, MD, MBA3; Brian Yeh, MD2; Daphna Y. Gelbum, MD4; Shaakir Hasan, DO1; J. Isabelle Choi, MD1; Chris A. Barker, MD4; Arpit M. Chhabra, MD1; Charles B. Simone II, MD, FACRO1; Nancy Y. Lee, MD, FASTRO4

1Department of Radiation Oncology, New York Proton Center, New York, New York, USA
2Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
3Department of Radiation Oncology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, USA
4Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA

Abstract

Radiotherapy is a common treatment modality in the management of head and neck malignancies. In select clinical scenarios of well-lateralized tumors, radiotherapy can be delivered to the primary tumor or tumor bed and the ipsilateral nodal regions, while intentional irradiation of the contralateral neck is omitted. Proton beam therapy is an advanced radiotherapy modality that allows for the elimination of exit-dose through nontarget tissues such as the oral cavity. This dosimetric advantage is apt for unilateral treatments. By eliminating excess dose to midline and contralateral organs at risk and conforming dose around complex anatomy, proton beam therapy can reduce the risk of iatrogenic toxicities. Currently, there is no level I evidence comparing proton beam therapy to conventional photon radiation modalities for unilateral head and neck cancers. However, a growing body of retrospective and prospective evidence is now available describing the dosimetric and clinical advantages of proton beam therapy. Subsequently, the intent of this clinical review is to summarize the current evidence supporting the use of proton beam therapy in unilateral irradiation of head and neck cancers, including evaluation of disease site-specific evidence, unique challenging clinical scenarios, and ongoing clinical trials.

Keywords: proton therapy; head and neck cancer; unilateral; ipsilateral; toxicities

Introduction

Radiation therapy is a critical component in the multidisciplinary management of head and neck malignancies. However, due to the inherent radiosensitivity of normal tissues in the head and neck region, radiation therapy for these diseases is often accompanied by significant morbidity. Common acute toxicities include mucositis, dysphagia, odynophagia, dermatitis, and xerostomia, among others. Additionally, as patients survive their disease, late complications can occur such as dental caries, osteoradionecrosis, and permanent dependence on percutaneous endoscopic gastrostomy (PEG) tubes. Many primary malignancies of the head and neck region originate in midline structures, placing lymphatic drainage on both sides of the neck at risk of subclinical disease and, therefore, necessitating the use of comprehensive bilateral neck irradiation. However, in select
clinical scenarios of lateralized disease with limited risk of contralateral neck involvement, ipsilateral elective nodal irradiation is a potential option to minimize treatment morbidity while maintaining comparable locoregional control [1]. Proton beam therapy (PBT) is an advanced form of radiation therapy, and its use for treatment of head and neck cancers is rapidly growing. The inherent physical properties of protons allow for rapid dose fall-off beyond the depth of the Bragg peak. Based on these unique dosimetric capabilities, PBT is an ideal treatment modality for the irradiation of unilateral head and neck targets, providing conformal target coverage while effectively eliminating unnecessary exit dose to midline (eg, oral cavity) and contralateral normal tissues that do not require treatment for oncologic control (Figure). Minimizing exit dose has the potential to significantly reduce the acute morbidity of treatment, minimize late chronic toxicities, and better preserve patient quality of life [2]. As many patients with indications for unilateral irradiation generally carry favorable prognoses, the reduction of chronic toxicities and prioritization of long-term quality of life outcomes after treatment is of growing importance [3]. To meet this need, PBT is a promising treatment modality in this patient population. While the evidence evaluating the role of PBT in the unilateral setting is currently limited, there has been a rapid growth of data the past several years as clinical interest has increased, providing compelling support for continued investigation. In this review, we present the current level of evidence for PBT in unilateral irradiation and discuss ongoing clinical trials.

**Literature Review Methods**

The following literature review was conducted to identify currently published studies reporting on clinical outcomes after unilateral proton therapy in head and neck malignancies. The primary search was performed using the electronic MEDLINE
PubMed database for all published literature through August 2020. Medical subject heading (MeSH) terms were used to identify peer-reviewed articles including “head and neck cancer,” “unilateral OR ipsilateral,” and “Proton therapy.” Abstracts were screened to include patients treated who had squamous cell carcinoma of the head and neck, cutaneous squamous cell carcinoma, salivary gland cancers, skull base tumors, and periocular tumors. Additional sources and clinical scenarios were subsequently identified from the references within initially captured studies. Currently active clinical trials were identified via Clinicaltrials.gov. Results were then summarized in descriptive format.

Dosimetric Studies
Dosimetric evaluations comparing PBT and conventional photon irradiation, such as intensity-modulated radiation therapy (IMRT), are critical to appreciate the potential dosimetric advantage of protons before testing whether and the degree to which improved dosimetry translates into a clinical advantage. Several dosimetric studies have been performed that compare PBT to photon-based IMRT in the treatment of unilateral target volumes [4–7]. Kandula et al [4] reported 5 patients with ipsilateral head and neck malignancies and compared treatment plans using pencil-beam scanning (PBS) PBT and IMRT. While PBT and IMRT achieved equal target coverage and similar conformity indices, mean doses to the contralateral organs at risk (OARs) were significantly lower with PBT, including reductions in mean doses to contralateral submandibular glands (639 cGy vs 4 cGy), contralateral parotid glands (533 cGy vs 49 cGy), and oral cavity (1760 cGy vs 459 cGy), as well as decreased maximum doses to the spinal cord (3692 cGy vs 2015 cGy) and brainstem (3412 cGy vs 1388 cGy) (all \(P<0.04\)). They also found a significant reduction in normal tissue integral dose with PBT.

Swisher-McClure et al [5] conducted a dosimetric comparison of IMRT with PBS-PBT for 8 patients with salivary gland cancers treated to a prescription dose of 6000 cGy. In this analysis, PBS-PBT achieved lower mean doses to the ipsilateral temporal lobe (959 cGy vs 286 cGy), oral cavity (1348 cGy vs 58 cGy), contralateral parotid gland (464 cGy vs 0 cGy), ipsilateral submandibular gland (3894 cGy vs 1659 cGy), and contralateral submandibular gland (534 cGy vs 2 cGy), as well as reduction in the mandible V50 (12.8% vs 7.4%) and maximum dose to the brainstem (3090 cGy vs 710 cGy) (all \(P<0.01\)).

Detailed dosimetric analysis by Owosho et al [6] also demonstrated reduced dose to tooth-bearing regions of the mouth with PBT compared with IMRT, particularly for the contralateral molars and premolars. This difference in ipsilateral molar mean dose between the 2 modalities was most prominent for patients with parotid gland tumors (1630 cGy vs 4980 cGy) compared with oropharyngeal (3190 cGy vs 5790 cGy) or oral cavity tumors (4530 cGy vs 5960 cGy), while the difference in dose to contralateral molars was more prominent for oropharynx (22 cGy vs 2320 cGy) compared with parotid (0 cGy vs 1180 cGy) or oral cavity (4 cGy vs 1560 cGy) primary tumors. Minimizing excess radiation dose to dental structures is clinically relevant to minimize the known risk of osteoradionecrosis and mitigate late deterioration in patient quality of life [8]. Osteoradionecrosis is a predominant late complication after head and neck irradiation and in a case-matched control study has been correlated with the volume of mandible receiving a wide range of doses, most prominently 5000 cGy [9].

In summary, dosimetric comparisons demonstrate superiority of PBT compared with IMRT in minimizing excess radiation dose to contralateral OARs, particularly mean doses, while maintaining conformal target coverage. On average, PBT reduces the mean dose to the oral cavity by 75% to 95% compared to that which can be achieved with IMRT. Similarly significant, the average reductions in dose to the contralateral parotid gland is >90%, and the average reduction in dose to the contralateral submandibular gland is >99%. In certain clinical circumstances, there are also advantages to reducing dose to ipsilateral submandibular glands when intentional coverage of lymph node level Iib is not indicated, with reductions of 50% to 60% compared with IMRT [4–6] (Table 1). These advantages appear consistent across different head and neck disease sites and are most prominent for low to moderate dose levels, corresponding with the rapid distal falloff of PBT beyond prescription dose volumes. These data support further clinical investigation to determine the clinical significance of these dosimetric improvements.

Clinical Outcomes
To date, there is no level I evidence supporting PBT over photon radiation modalities to treat unilateral head and neck cancers. Despite the lack of randomized data, there is a growing level of retrospectively and prospectively collected observational literature to describe clinical outcomes after unilateral PBT across a range of head and neck malignancies (Table 2).
Salivary Tumors

Salivary gland tumors consist of a heterogeneous group of histologies, including mucoepidermoid carcinoma, adenoid cystic carcinoma, adenocarcinoma, salivary duct carcinoma, and acinic cell carcinoma, among others. They can occur in major or minor salivary glands. Adjuvant radiotherapy is generally used for intermediate to high-grade, recurrent, perineural invasive, microscopic positive margins, and/or subtotally resected tumors. Major salivary gland tumors are generally positioned at shallow depths, lateral to the oral cavity and other midline structures, and effectively carry no risk of contralateral nodal spread, making these disease entities optimal targets for unilateral PBT irradiation. Dagan et al [10] prospectively collected rates of acute toxicities of patients with parotid gland tumors treated with PBT at the University of Florida. They examined 23 patients who received primary (n = 7) or adjuvant (n = 16) PBT for parotid cancers, most commonly salivary gland carcinomas. Median dose was 7000 cGy, and 7 patients received concurrent chemotherapy. The mean doses to the oral cavity (750 cGy), larynx (10 cGy), contralateral parotid gland (180 cGy), and contralateral submandibular gland (180 cGy) were low, consistent with prior dosimetric studies. Associated rates of acute toxicities were consistently low, with most patients experiencing no greater than grade 1 mucositis, dysphagia, dysgeusia, and xerostomia. There was only 1 grade 3 toxicity, an event of transient grade 3 dysphagia that lasted 1 week and occurred in a patient with baseline grade 2 dysphagia. Median weight loss was 3% from baseline in the cohort, and no patients required a PEG tube. Most patients reported either no mucositis (35% to 43%) or grade 1 mucositis (17% to 30%) as per weekly evaluations during the entire treatment course. Of note, dermatitis was not described in this report.

The multi-institutional Proton Collaborative Group registry also reported prospectively collected rates of acute toxicities in patients with salivary gland tumors treated with ipsilateral PBT. In total, 105 patients (90 parotid, 15 submandibular) were treated either in the postoperative (71%) or definitive (29%) setting to a median dose of 66 Gy. The most common acute grade 2 toxicities included dermatitis (58%), esophagitis/pharyngitis (13.3%), oral mucositis (10.5%), dysphagia (8.9%), xerostomia (7.6%), dysgeusia (4.8%), and otalgia (4.8%). Grade 3 toxicities included dermatitis (10.5%), mucositis (2.9%), and dysphagia (1.9%). There were no acute grade 4 or higher toxicities [12].

### Table 1. Summary of dosimetric studies for ipsilateral head and neck irradiation.

| Radiation Modality | Kandula et al [4] | Swisher-McClure et al [5] | Romesser et al [7] | Dagan et al [10] | Grant et al [11] |
|--------------------|-------------------|---------------------------|-------------------|-----------------|-----------------|
| Oral cavity (mean) | PBS vs IMRT       | PBS vs IMRT               | USPT vs IMRT      | PSPT            | PSPT/PBS vs EBT/IMRT |
| Photon             | 1760              | 1348                      | 2060              | NR              | 2070            |
| Proton             | 458               | 58                        | 94                | 750             | 460             |
| Contralateral parotid gland (mean) | | | | | |
| Photon             | 533               | 464                       | 140               | NR              | 460             |
| Proton             | 49                | 0                         | 0                 | 10              | 0               |
| Contralateral submandibular gland (mean) | | | | | |
| Photon             | 639               | 534                       | 410               | NR              | 1350            |
| Proton             | 4                 | 2                         | 0                 | 180             | 0               |
| Ipsilateral submandibular (mean) | | | | | |
| Photon             | NR                | 3894                      | NR                | NR              | NR              |
| Proton             | NR                | 1659                      | NR                | NR              | NR              |
| Larynx (mean)      | Photon            | NR                        | 2140              | NR              | 4430            |
| Proton             | NR                | NR                        | 1030              | 720             | 1130            |
| Spinal cord (maximum) | Photon | NR            | 3630              | NR              | 3940            |
| Proton             | 2014              | NR                        | 190               | NR              | 81              |
| Brainstem (maximum) | Photon | 3412          | 3091              | 2970            | NR              |
| Proton             | 1388              | 710                       | 62                | NR              | NR              |

**Abbreviations:** PBS, pencil beam scanning; IMRT, intensity-modulated radiation therapy; USPT, uniform scanning proton therapy; PSPT, passive scattered proton therapy; EBT, electron beam therapy; NR, not reported.
Press et al (2021), *Int J Particle Ther*
### Table 2. Studies evaluating proton therapy for unilateral head and neck malignancies.

| Study          | Year | Type      | Disease Site   | Patients | Radiation Modality | Dose (median) | Surgery (%) | Follow-up (median) | Outcomes | Acute Toxicity | Late Toxicity |
|----------------|------|-----------|----------------|----------|--------------------|---------------|--------------|-------------------|-----------|----------------|---------------|
| Dagan et al [10] | 2016 | Prospective | No Salivary    | n = 23   | PSPT               | 7000 cGy      | 70           | 30               | NR (weekly assessments on treatment) | NR | Most patients experienced no greater than G1 toxicity. By treatment completion, G2 toxicity included mucositis (35%), dysphagia (26%), dysgeusia (23%), and xerostomia (14%). One patient with baseline G2 dysphagia developed transient G3 dysphagia. Median weight loss was 3%. No patient required PEG tube placement. |
| Chuong et al [12] | 2020 | Prospective | No Salivary    | n = 105  | USPT (n = 70) PBS (n = 35) | 8650 cGy      | 70.5         | 20               | NR | Acute G2–3 nausea (1.5%), dysgeusia (4.8%), xerostomia (7.6%), mucositis (10.5%), dysphagia (10.5%). Acute G3 dermatitis (10.5%), dysphagia 1.9%, fatigue 1%, and mucositis 2.9%. |
| Holliday et al [13] | 2016 | Retrospective | No Salivary    | n = 16   | IMPT               | 6000 cGy      | 100          | 63               | 24.9 mo | 1 patient developed LF; remaining 15 patients had no evidence of disease (LC and OS of 94%) | Cumulative acute G3 toxicity 25%, including 1 patient with G3 mucositis (6%) and 3 patients with G3 dermatitis (19%). Cumulative late G3–4 toxicity 6.3% (1 patient developed optic neuropathy after optic nerve max dose of 7300 cGy) |
| Grant et al [11] | 2015 | Retrospective | Yes Salivary    | n = 24   | PSPT (n = 8) IMPT (n = 5) IMRT (n = 3) IMRT/EBT (n = 7) EBT (n = 1) | 6000 cGy      | 100          | 8               | 35 mo (PBT = 8 mo X/E = 8 y) | NR | Less G2–3 mucositis after PBT (46% vs 91%; P < .05), numeric reduction in G2–3 dysphagia after PBT (0% vs 27%; P = .08), no difference in G2–3 dermatitis (54% vs 55%; P = 1.0), or G2–3 otitis externa (8% vs 18%; P = .58). |
| Romesser et al [7] | 2016 | Retrospective | Yes Salivary    | n = 41   | USPT (n = 18) IMRT (n = 23) | 6600 cGy      | 90           | 20               | 8.7 mo (PBT = 4.7 mo IMRT = 16.1 mo) | 1-y LC = 92.8% 1-y freedom from distant metastases = 87.8% 1-y OS = 89.4% Non-significant between cohorts | Less G2–3 acute dysgeusia (5.6% vs 65.2%; P < .001), mucositis (16.7% vs 52.2%; P = .003), and nausea (11% vs 56.5%; P = .003) after PBT. Increased G2–3 dermatitis after PBT (100% vs 74%; P = .002) |
| Holliday et al [27] | 2016 | Retrospective | No Periorbital malignancies | n = 29   | PSPT (n = 14) IMPT (n = 6) | 6000 cGy      | 100          | 55               | 27.1 mo | No patient developed LF. 1 patient developed regional recurrence and 1 patient developed distant metastasis | Acute G3 dermatitis (35%). No acute G3 ocular disorders occurred. 8 patients developed late G3 ocular toxicity (30%), including 3 patients with G3 epiphora and 3 patients with G3 eyelid dysfunction/keratopathy. 5 patients developed declines in visual acuity from baseline (25%). |
Proton review for unilateral cancers

Table 2. Continued.

| Study | Year | Type | pw/Ps | Disease Site | Patients | Radiation Modality | Dose (median) | Surgery (%) | Chemotherapy (%) | Follow-up (median) | Outcomes | Acute Toxicity | Late Toxicity |
|-------|------|------|-------|--------------|----------|--------------------|--------------|-------------|-----------------|-------------------|-----------|----------------|---------------|
| Manzar et al [32] | 2020 | Retrospective (clinical data) prospective (PROs) | Yes | Oropharynx | n = 259 (unilateral - 44) | VMAT (n = 6) | 7000 cGy | IMPT | IMPT | IMPT | NR | In the unilateral cohort, there was decreased MEQ narcotic use (P < .05) and numeric reduction in PEG tube placement (% vs 36.8%; P = .083) after IMPT. Reduced mucositis, oral pain, pharyngeal pain, weight loss, and pain after IMPT (all P < .05), trend toward less fatigue after IMPT (P = .058) but increased dermatitis and duct inflammation after IMPT (all P < .05). Improved PROs, including dry mouth, sticky saliva, sense of smell/taste after IMPT (all P < .05) |
| | | | | | | VMAT (n = 38) | | VMAT | VMAT | VMAT | | |
| | | | | | 57 | 55 | 69 | 67 | 30 mo | | |
| | | | | | (entire cohort) | (entire cohort) | (entire cohort) | (entire cohort) | | |

Abbreviations: PSPT, passive scatter proton therapy; NR, not reported; G1, grade 1; G2, grade 2; G3, grade 3; PEG, percutaneous endoscopic gastrostomy; USPT, uniform scatter proton therapy; PBS, pencil beam scanning; IMPT, intensity-modulated proton therapy; ACC, adenoide cystic carcinoma; LF, local failure; LC, local control; OS, overall survival; PBT, proton beam therapy; IMRT, intensity-modulated radiation therapy; X/E, photon/electron; EBT, electron beam therapy; cSCC, cutaneous squamous cell carcinoma; PRO, patient-reported outcome; VMAT, volumetric modulated arc therapy; MEQ, morphine equivalent.

Skull Base Perineural Invasion

Another promising use of PBT is in cases of perineural involvement along cranial nerves. Often, gross and/or microscopic PNI occurs along the cranial nerves ipsilateral to the primary tumor. Treatment of this disease presentation is challenging due to the need for high-dose radiotherapy around complex anatomy and in close proximity to critical neurologic OARs [16, 17]. The most commonly involved nerves include the trigeminal and facial nerves, but this varies based on the location and extent of the primary disease. Due to limited salvage options, survival is highly correlated with local control [18]. Historical studies using 3-dimensional conformal radiation therapy (3DCRT)/IMRT report local control ranging from 54% to 80% and late complication rates of 16% to 35% when treating radiographic and clinical PNI [19]. Retrospective reports using PBT to conformally cover disease extension to the base of skull have demonstrated promising local control rates of PNI upwards of 90% [20].

The major advantage of PBT in these scenarios is the ability to achieve maximal target coverage—unlike the sacrifice of tumor volume coverage that is typically necessary with photon therapy—while still meeting goal OAR constraints. PBT may therefore be more likely to achieve tumor control while minimizing the risk of late toxicities. Radiation-induced optic neuropathy is a major complication after skull base radiotherapy and can have a major impact on functional ability and quality of life. Two large studies by Kountouri et al [21] at Paul Scherrer Institute (n = 216) and Li et al [22] at Massachusetts General Hospital (n = 514) have now reported consistently low rates of radiation-induced optic neuropathy (~1%) after high-dose PBT when the maximum dose to optic structures remains <5900 to 6000 cGy.

Additionally, lower cranial neuropathies involving cranial nerves IX, X, XI, and XII can occur after skull base irradiation. Common manifestations include chronic dysphagia, aspiration, dysphonia, and shoulder impairment. Lower cranial neuropathies are difficult to study given their low incidence (~4% to 5%) and prolonged time to presentation (median 5 to 7 years) [23]. Despite this, they have been associated with significant detriment in long-term survivor quality of life [24] and likely remain underreported [25]. Studies with extended follow-up have correlated lower cranial neuropathies with total dose to OARs [25, 26], representing another potential opportunity to use PBS PBT’s dosimetric capabilities to reduce dose to skull base foramina and pharyngeal constrictor musculature and improve long-term outcomes.

Periorbital Tumors

Periorbital cutaneous and epithelial tumors pose a similar treatment challenge due to their location near complex critical normal tissues, including the globe, cornea, lacrimal gland, and nasolacrimal ducts. Tumors can involve the lacrimal gland, lacrimal sac, conjunctiva, and/or eyelid. Some patients may benefit from adjuvant radiotherapy for high-risk features such as...
positive margins/residual disease, high-grade disease, and/or positive lymph nodes. Radiotherapy can also be used for organ preservation when orbital exenteration would be otherwise required for oncologic control.

In a separate report, Holliday et al. [27] described the MDACC experience treating 20 patients with periorbital tumors with PBT after globe-sparing surgery. There were no local recurrences, and only 2 patients developed regional or distant disease. Seven patients (35%) developed grade 3 radiation dermatitis, and 6 patients (30%) developed grade 3 ocular toxicities. This included 3 patients with grade 3 epiphora, 3 patients with grade 3 exposure keratopathy, and 5 patients with a decrease in visual acuity. Visual acuity declined from baseline in 2 patients from 20/20 to 20/40 as well as in 1 patient each from 20/25 to 20/80, 20/60 to 20/200, and 20/25 to 20/400. Importantly, no patients developed complete blindness, and all maintained sufficient visual acuity to perform activities of daily living. Grade 3 or higher ocular toxicity was associated with maximum dose to the ipsilateral cornea (median 4630 cGy vs 3740 cGy; \( P = .017 \)). Notably, there was a strong numeric trend toward increased grade 3 toxicity in patients treated with passive scatter PBT (\( n = 14 \)) compared with IMPT (\( n = 6 \)) (43% vs 0%; \( P = .055 \)) [27]. Dose to the conjunctiva >35 Gy and lacrimal duct system >45 Gy have been previously associated with late complications, including conjunctival telangiectasias, conjunctival keratinization, and dry eye syndrome [28, 29]. These early reports suggest that PBT widens the therapeutic ratio in these difficult scenarios and, in select cases, provides a chance for organ preservation when conventional adjuvant radiotherapy would otherwise not be feasible.

Oropharyngeal Cancer

Cancers of the oropharynx are another disease entity which may benefit from PBT. Well defined criteria are available to identify ideal candidates for unilateral elective nodal irradiation [30]. In addition, human papillomavirus–associated disease typically has a good prognosis, and, therefore, mitigation of late toxicities is an important consideration. As current studies are investigating methods to successfully deintensity definitive therapy, patients with well-lateralized tonsil cancer who can be appropriately treated with unilateral irradiation may potentially receive an even greater level of deintensification of toxicity with PBT. Descriptions of clinical outcomes in oropharyngeal cancer after PBT is growing; however, most comparisons to date do not distinguish between field laterality, and, thus, unilateral-specific analyses are limited.

A case-matched analysis describing the MDACC experience reported by Blanchard et al. [31] examined 50 IMPT and 1000 IMRT patients, 20% of whom received unilateral irradiation. In the overall cohort, patients treated with PBT demonstrated a significantly decreased chance of requiring PEG tube placement during treatment (odds ratio [OR] = 0.53; \( P = .011 \)) and a significant reduction in the preplanned composite endpoint of grade 3 weight loss or PEG placement at 3 months (OR = 0.44) and at 1 year (OR = 0.23; \( P < .05 \)). There was no difference in progression free survival or overall survival [32].

In addition, favorable patient-reported outcomes (PROs) after PBT have been demonstrated, including significant reductions in acute and subacute mucositis, xerostomia, dysgeusia, appetite, dental problems, fatigue, and physical function [32–35]. The largest study to date was a comparative analysis by Manzar et al. [32] reporting the Mayo Clinic experience of provider-reported toxicities and PROs after IMPT (\( n = 46 \)) and volumetric modulated arc therapy (VMAT) (\( n = 259 \)). In the unilateral cohort (\( n = 44 \)), significant improvements in PRO domains were identified for IMPT compared with VMAT, including dry mouth, sticky saliva, and altered taste (\( P < .05 \)). Improvements in provider-reported toxicity favored IMPT for mucositis, oral pain, pharyngeal pain, weight loss, and fatigue, while VMAT was favored for dermatitis. There was also decreased morphine equivalent narcotic use by the end of treatment (\( P < .05 \)) as well as a strong numeric trend in reduction of PEG-tube placement for IMPT vs VMAT (0% vs 36.8%; \( P = .083 \)).

Bagley et al. [33] described the evolution of patient-reported xerostomia scores using the Xerostomia-Related QoL Scale (XeQoLS) questionnaire in 69 patients treated with IMPT, including 12 treated with unilateral irradiation. They described expected initial worsening of scores at 6 weeks, followed by improvements over the following 2 years that approached but did not fully return to baseline. Scores were correlated with clinical factors, including mean oral cavity dose (\( P = .038 \)), but surprisingly not laterality.

While it can be assumed that the overall magnitude of morbidity in patients treated with ipsilateral irradiation is less compared with patients treated with bilateral irradiation, the absolute difference between treatment modalities in the unilateral setting is yet to be defined. The current evidence in support of PBT, particularly benefits in PROs, is notable and warrants further investigation via randomized trials.

Reirradiation

Locoregional recurrence remains the primary pattern of failure for head and neck cancers after definitive radiotherapy. In select patients, reirradiation provides a chance for durable tumor control but is also associated with significant high-grade toxicities—including potential grade 5 events such as carotid blowout. Accounting for the increased risk for this scenario, reirradiation...
treatment volumes classically target the primary/recurrent tumor or high-risk tumor bed alone without prophylactic subclinical or nodal coverage [36]. This often effectively results in unilateral target volumes. PBT is a logical treatment modality in these challenging scenarios to minimize dose overlap with previous radiotherapy courses.

There is increasing single-institutional and multi-institutional level II evidence supporting the use of PBT reirradiation. Phan et al [37] presented 60 patients prospectively enrolled and treated at MDACC with PBT for recurrent or secondary head and neck cancers. Most patients had salvage surgery (58%) and received concurrent chemotherapy (73%). The median interval from the prior course of radiotherapy was 47 months. Clinical outcomes were promising, including 1-year local control and overall survival of 68.4% and 83.8%, respectively, and grade 3 and grade 5 toxicity of 30% and 5%, respectively.

In another report, Romesser et al [38] described the multi-institutional experience of MSKCC, ProCure Proton Therapy Center, and the University of Pennsylvania. A total of 92 patients were included, 39% of whom had salvage surgery, with a median interval of 34 months. The 1-year rate of locoregional failure, with death as a competing risk, was 25.1% and the 1-year overall survival was 65.2%. Acute grade 3 or greater mucositis (9.9%), dysphagia (9.1%), esophagitis (9.1%), and dermatitis (3.3%) were low, and 2 patients developed grade 5 bleeding (2%). MSKCC is currently conducting a prospective phase II nonrandomized multiarm study for patients with recurrent and second primary head and neck cancers, including a cohort receiving full-dose PBT reirradiation. The primary endpoint of this arm is 1-year locoregional recurrence free rate.

While randomized trials to date have not demonstrated a survival benefit to chemo-reirradiation using 3DCRT [39], historical rates of high-grade toxicities approached 40% and may have undermined the improvement in locoregional control. Therefore, more conformal dose delivery with PBT may reduce late high-grade toxicities and widen the therapeutic window. Patient selection is also critical in determining which patients may benefit most from reirradiation. Dosimetric comparison studies and, ultimately, randomized trials comparing IMRT and PBT in the reirradiation setting are warranted to quantify differential outcomes and identify optimal PBT candidates.

**Randomized Trials**

Ultimately, randomized trials will be important to confirm the clinical advantages of PBT in the unilateral setting. To date, there is no published level I evidence comparing PBT to IMRT in head and neck cancers. It is important to note, however, that there are no randomized trials supporting the use of IMRT to conventional 2-dimensional and 3-dimensional radiotherapy techniques in the unilateral setting, and yet IMRT is now well established as the standard of care for treating unilateral head and neck tumors.

To address the need for randomized data, MSKCC, in collaboration with ProCure Proton Therapy Center and The New York Proton Center, is currently conducting a prospective randomized phase II trial using a direct 1:1 randomization between the 2 treatment modalities (NCT02923570) [40] evaluating outcomes in patients with surgically resected salivary gland cancer, skin cancer, or melanoma requiring unilateral postoperative irradiation. The primary outcome compares the rate of acute grade 2 or greater mucositis (per the Common Terminology Criteria for Adverse Events [CTCAE], version 4.0; National Cancer Institute). The secondary outcomes assess the rate of other grade 2 or higher acute physician-reported toxicities, the rate of acute grade 2 or higher patient-reported toxicities (per the PRO-CTCAE; National Cancer Institute), the correlation between physician- and patient-reported toxicities, and the rate of late toxicities and clinical outcomes.

ARTSCAN V (NCT03829033) [41] is another ongoing multicenter randomized trial in Sweden comparing PBT to photon therapy using a 1:1 randomization. Eligibility includes T1-2, N0-1 squamous cell carcinoma of the tonsil planned for ipsilateral treatment with definitive radiotherapy alone. The primary endpoints are acute and late toxicities graded according to CTCAE.

In addition, RTOG 1008 (NCT01220583) [42] is an ongoing phase II randomized trial of postoperative radiation for high-risk salivary gland tumors with or without weekly cisplatin. While not directly studying PBT, a recent amendment allows the inclusion of patients treated with PBT. The expectation will be to assess clinical outcomes across treatment modalities, which will provide further prospective data to quantify the value of PBT in this clinical scenario.

**Discussion**

Both prospectively collected single-arm studies and retrospective comparative analyses now demonstrate compelling reductions in acute toxicities in favor of PBT, particularly for mucositis, dysgeusia, xerostomia, nausea, and fatigue. In select clinical scenarios, single-arm studies demonstrate impressively low rates of chronic toxicities for optic and orbital structures and a safer path to organ preservation without compromising tumor control rates. Formal evaluations of late mucosal and
glandular toxicities are still generally lacking, and the optimism for PBT to mitigate these late effects in the unilateral setting must currently be extrapolated from the limited data in the bilateral setting.

The lack of long-term follow-up is due, in part, to the contemporary nature of PBT technology along with the limited regional access resulting in fewer patients and shorter follow-up time available [43]. Late toxicities such as chronic dysphagia can be challenging to capture given the extended time to develop and/or progress symptoms as well as its association with baseline function [44]. As PBT centers become more available across the United States, ongoing prospective studies accrue, and further PBT technical advances are achieved, we expect a rapid rise in data that can more definitively evaluate the effect of PBT on reducing the risk of late toxicity.

It is important to note that acute dermatitis does not appear to be reduced by PBT and, in several studies, is reported to be worse. This may be related to the passive scatter technology used in older studies. Further research on the optimization of skin dose in PBT using PBS planning is needed. Similar to the differences in technical capabilities and resulting clinical toxicity outcomes between photon-based 3DCRT and IMRT, significant improvements in dose modulation capabilities and toxicity profiles are apparent between older generation passive scatter PBT and modern IMPT. Future studies must therefore make the distinction between different generations of technology when reporting outcomes to fully appreciate the potentials of modern PBT.

In summary, retrospective and uncontrolled prospective data support the use of PBT for patients with head and neck malignancies requiring unilateral irradiation. The extent of clinical improvement from the well-documented dosimetric advantages and comparative analyses require further quantification and confirmation in randomized trials. Several randomized studies are currently active, and we await these results to confirm the reduction in acute toxicities and quantify the possible differences in chronic toxicities.

ADDITIONAL INFORMATION AND DECLARATIONS

Conflicts of Interest: Charles B. Simone II, MD, FACRO, reports a Varian Medical Systems honorarium outside of the submitted work. Chris A. Barker, MD, reports grants and nonfinancial support from Alpha Tau Medical, grants from Merck, grants from Amgen, grants from Elekta, and personal fees and nonfinancial support from Regeneron, outside of the submitted work. The authors have no additional conflicts of interest to disclose.

Funding: The authors have no funding to disclose.

Ethical approval: This study was reviewed by the authors’ institutional research infrastructure and was determined to be exempt from IRB approval.

References

1. Huang SH, Waldron J, Bratman SV, Su J, Kim J, Bayley A, Cho J, Giuliani M, Hope A, Ringash J, Hansen A, de Almeida JR, Goldstein D, Perez-Ordonez B, Weinreb I, Tong L, Xu W, O’Sullivan B. Re-evaluation of ipsilateral radiation for T1-T2N0-N2b tonsil carcinoma at the Princess Margaret Hospital in the human papillomavirus era, 25 years later. Int J Radiat Oncol Biol Phys. 2017;98:159–169. doi:10.1016/j.ijrobp.2017.01.018

2. Verma V, Simone CB II, Mishra M V. Quality of life and patient-reported outcomes following proton radiation therapy: a systematic review. J Natl Cancer Inst. 2018;110(4). doi:10.1093/jnci/djx208

3. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, Leemans CR, Aaronson NK, Slotman BJ. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol Off J Am Soc Clin Oncol. 2008;26:3770–3776. doi:10.1200/JCO.2007.14.6647

4. Kandula S, Zhu X, Garden AS, Gillin M, Rosenthal DI, Ang K-K, Mohan R, Amin MV, Garcia JA, Wu R, Sahoo N, Frank SJ. Spot-scanning beam proton therapy vs intensity-modulated radiation therapy for ipsilateral head and neck malignancies: a treatment planning comparison. Med Dosim Off J Am Assoc Med Dosim. 2013;38:390–394. doi:10.1016/j.meddos.2013.05.001

5. Swisher-McClure S, Teo B-KK, Kirk M, Chang C, Lin A. Comparison of pencil beam scanning proton- and photon-based techniques for carcinoma of the parotid. Int J Part Ther. 2016;2:525–532. doi:10.14338/IJPT-15-00005.1

6. Owosho AA, Yom SK, Han Z, Sine K, Lee NY, Huryn JM, Estilo CL. Comparison of mean radiation dose and dosimetric distribution to tooth-bearing regions of the mandible associated with proton beam radiation therapy and intensity-modulated radiation therapy for ipsilateral head and neck tumor. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122:566–571. doi:10.1016/j.oooo.2016.07.003
7. Romesser PB, Cahlon O, Scher E, Zhou Y, Berry SL, Rybkin A, Sine KM, Tang S, Sherman EJ, Wong R, Lee NY. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. *Radiother Oncol J Eur Soc Ther Radiol Oncol*. 2016;118:286–292. doi:10.1016/j.radonc.2015.12.008

8. Duke RL, Campbell BH, Indresano AT, Eaton DJ, Marbella AM, Myers KB, Layde PM. Dental status and quality of life in long-term head and neck cancer survivors. *Laryngoscope*. 2005;115:678–683. doi:10.1097/01.mlg.0000161354.28073.bc

9. Tsai CJ, Hofstede TM, Sturgis EM, Garden AS, Lindberg ME, Wei Q, Tucker SL, Don L. Osteoradionecrosis and radiation dose to the mandible in patients with oropharyngeal cancer. *Int J Radiat Oncol Biol Phys*. 2013;85:415–420. doi:10.1016/j.ijrobp.2012.05.032

10. Dagan R, Bryant CM, Bradley JA, Indelicato DJ, Rutenberg M, Rotondo R, Morris CG, Mendenhall WM. A prospective evaluation of acute toxicity from proton beam therapy for targets of the parotid region. *Int J Part Ther*. 2016;3:285–290. doi:10.14338/IJPT-16-00010.2

11. Grant SR, Grosshans DR, Bilton SD, Garcia JA, Amin M, Chambers MS, McGovern SL, McAleer MF, Morrison WH, Huh WW, Kupferman ME, Mahajan A. Proton versus conventional radiotherapy for pediatric salivary gland tumors: acute toxicity and dosimetric characteristics. *Radiother Oncol J Eur Soc Ther Radiol Oncol*. 2015;116:309–315. doi:10.1016/j.radonc.2015.07.022

12. Chuong M, Bryant J, Hartsell W, et al. Minimal acute toxicity from proton beam therapy for major salivary gland cancer. *Acta Oncol*. 2020;59:196–200. doi:10.1080/0284186X.2019.1698764

13. Holliday E, Bhattasali O, Kies MS, Hanna E, Garden AS, Rosenthal DI, Morrison WH, Gunn GB, Phan J, Zhu XR, Zhang X, Frank SJ. Postoperative intensity-modulated proton therapy for head and neck adenoid cystic carcinoma. *Int J Part Ther*. 2016;2:533–543. doi:10.14338/IJPT-15-00032.1

14. Alterio D, Jereczek-Fossa BA, Griseri M, D’Onofrio A, Giugliano G, Fiore MR, Vitolo V, Fossati P, Piperno G, Calabrese LS, Verri E, Chiesa FG, Orecchia LS. Three-dimensional conformal postoperative radiotherapy in patients with parotid tumors: 10 years’ experience at the European Institute of Oncology. *Tumori*. 2011;97:328–334. doi:10.1700/912.10030

15. Schoenfeld JD, Sher DJ, Norris CMJ, Haddad RI, Posner MR, Balboni TA, Tishler RB. Salivary gland tumors treated with adjuvant intensity-modulated radiotherapy with or without concurrent chemotherapy. *Int J Radiat Oncol Biol Phys*. 2012;82:308–314. doi:10.1016/j.ijrobp.2010.09.042

16. Holtzman AL, Mendenhall WM. High-dose conformal proton therapy for clinical perineural invasion in cutaneous head and neck cancer. *Oral Oncol*. 2020;100:104486. doi:10.1016/j.oraloncology.2019.104486

17. Bakst RL, Glastonbury CM, Parvathaneni U, Katabi N, Hu KS, Yom SS. Perineural invasion and perineural tumor spread in head and neck cancer. *Int J Radiat Oncol Biol Phys*. 2019;103:1109–1124. doi:10.1016/j.ijrobp.2018.12.009

18. Karia PS, Morgan FC, Ruiz ES, Schmults CD. Clinical and incidental perineural invasion of cutaneous squamous cell carcinoma: a systematic review and pooled analysis of outcomes data. *JAMA Dermatology*. 2017;153:781–788. doi:10.1001/jamadermatol.2017.1680

19. Balamucki CJ, Mancuso AA, Amdur RJ, et al. Skin carcinoma of the head and neck with perineural invasion. *Am J Otolaryngol*. 2012;33:447–454. doi:10.1016/j.amjoto.2011.11.004

20. Pommier P, Liebsch NJ, Deschler DG, Lin DT, McIntyre JF, Barker FG 2nd, Adams JA, Lopes V V, Varvares M, Loeffler JS, Chan AW. Proton beam radiation therapy for skull base adenoid cystic carcinoma. *Arch Otolaryngol Head Neck Surg*. 2006;132:1242–1249. doi:10.1001/archotol.132.11.1242

21. Kountouri M, Pica A, Walser M, Albertini F, Bolsi A, Kliebsch U, Combescure C, Lomax AJ, Schneider R, Weber DC. Radiation-induced optic neuropathy after pencil beam scanning proton therapy for skull-base and head and neck tumours. *Br J Radiol*. 2019;93:20190028. doi:10.1259/bjr.20190028

22. Li PC, Liebsch NJ, Niemierko A, Giantstoudi D, Lessell S, Fullerton BC, Adams J, Shih HA. Radiation tolerance of the optic pathway in patients treated with proton and photon radiotherapy. *Radiother Oncol J Eur Soc Ther Radiol Oncol*. 2019;131:112–119. doi:10.1016/j.radonc.2018.12.007

23. Hutcheson KA, Yuk M, Hubbard R, Gunn GB, Fuller CD, Lai SY, Lin H, Garden AS, Rosenthal DI, Hanna YE, Kies MS, Lewin JS. Delayed lower cranial neuropathy after oropharyngeal intensity-modulated radiotherapy: a cohort analysis and literature review. *Head Neck*. 2017;39:1516–1523. doi:10.1002/hed.24789
24. Aggarwal P, Zaveri JS, Goepfert RP, Shi Q, Du XL, Swartz M, Gunn GB, Lai SY, Fuller CD, Hanna EY, Rosenthal DI, Lewin JS, Piller LB, Hutcheson KA. Symptom burden associated with late lower cranial neuropathy in long-term oropharyngeal cancer survivors. *JAMA Otolaryngol Head Neck Surg*. 2018;144(11):1066–1076. doi:10.1001/jamaoto.2018.1791

25. Dong Y, Ridge JA, Ebersole B, Li T, Lango MN, Churilla TM, Donocoff K, Bauman JR, Galloway TJ. Incidence and outcomes of radiation-induced late cranial neuropathy in 10-year survivors of head and neck cancer. *Oral Oncol*. 2019;95:59–64. doi:10.1016/j.oraloncology.2019.05.014

26. Awan MJ, Mohamed ASR, Lewin JS, Baron CA, Gunn GB, Rosenthal DI, Holsinger FC, Schwartz DL, Fuller CD, Hutcheson KA. Late radiation-associated dysphagia (late-RAD) with lower cranial neuropathy after oropharyngeal radiotherapy: a preliminary dosimetric comparison. *Oral Oncol*. 2014;50:746–752. doi:10.1016/j.oraloncology.2014.05.003

27. Holliday EB, Esmaeili B, Pinckard J, Garden AS, Rosenthal DI, Morrison WH, Kies MS, Gunn GB, Fuller CD, Phan J, Beadle BM, Zhu XR, Zhang X, Frank SJ. A multidisciplinary orbit-sparing treatment approach that includes proton therapy for epithelial tumors of the orbit and ocular adnexa. *Int J Radiat Oncol Biol Phys*. 2016;95:344–352. doi:10.1016/j.ijrobp.2015.08.008

28. Jeganathan VSE, Wirth A, MacManus MP. Ocular risks from orbital and periorbital radiation therapy: a critical review. *Int J Radiat Oncol Biol Phys*. 2011;79:650–659. doi:10.1016/j.ijrobp.2010.09.056

29. Bhandare N, Moiseenko V, Song WY, Morris CG, Bhatti MT, Mendenhall WM. Severe dry eye syndrome after radiotherapy for head-and-neck tumors. *Int J Radiat Oncol Biol Phys*. 2012;82:1501–1508. doi:10.1016/j.ijrobp.2011.05.026

30. Sher DJ, Adelstein DJ, Bajaj GK, Brizel DM, Cohen EEW, Halthore A, Harrison LB, Lu C, Moeller BJ, Quon H, Rocco JW, Sturgis EM, Tishler RB, Trotti A, Waldron J, Eisbruch A. Radiation therapy for oropharyngeal squamous cell carcinoma: executive summary of an ASTRO evidence-based clinical practice guideline. *Pract Radiat Oncol*. 2017;7:246–253. doi:10.1016/j.prro.2017.02.002

31. Blanchard P, Garden AS, Gunn GB, Rosenthal DI, Morrison WH, Hernandez M, Crutison J, Lee JJ, Ye R, Fuller CD, Mohamed ASR, Hutcheson KA, Holliday EB, Thaker NG, Sturgis EM, Kies MS, Zhu XR, Mohan R, Frank SJ. Intensity-modulated proton beam therapy (IMPT) versus intensity-modulated photon therapy (IMRT) for patients with oropharynx cancer—a case matched analysis. *Radiother Oncol J Eur Soc Ther Radiol Oncol*. 2016;120:48–55. doi:10.1016/j.radonc.2016.05.022

32. Manzar GS, Lester SC, Routman DM, Petersen MM, Sloan JA, Mundy DW, Hunzeker AE, Amundson AC, Anderson JL, Patel SH, Garces YI, Halyard MY, McGee LA, Neben-Wittich MA, Ma DJ, Frank SJ, Whitaker TJ, Foote RL. Comparative analysis of acute toxicities and patient reported outcomes between intensity-modulated proton therapy (IMPT) and volumetric modulated arc therapy (VMAT) for the treatment of oropharyngeal cancer. *Radiother Oncol J Eur Soc Ther Radiol Oncol*. 2020;147:64–74. doi:10.1016/j.radonc.2020.03.010

33. Bagley AF, Ye R, Garden AS, Gunn GB, Rosenthal DI, Fuller CD, Morrison WH, Phan J, Sturgis EM, Ferrarotto R, Wu R, Liu AY, Frank SJ. Xerostomia-related quality of life for patients with oropharyngeal carcinoma treated with proton therapy. *Radiother Oncol J Eur Soc Ther Radiol Oncol*. 2020;142:133–139. doi:10.1016/j.radonc.2019.07.012

34. Sharma S, Zhou O, Thompson R, Gabriel P, Chalian A, Rassekh C, Weinstein GS, O'Malley BWJ, Aggarwal C, Bauml J, Cohen RB, Lukens JN, Swisher-McClure S, Ghiam AF, Ahn PH, Lin A. Quality of life of postoperative photon versus proton radiation therapy for oropharynx cancer. *Int J Part Ther*. 2018;5:11–17. doi:10.14338/IJPT-18-00032.1

35. Sio TT, Lin H-K, Shi Q, Gunn GB, Cleeland CS, Lee JJ, Hernandez M, Blanchard P, Thaker NG, Phan J, Rosenthal DI, Garden AS, Morrison WH, Fuller CD, Mendoza TR, Mohan R, Wang XS, Frank SJ. Intensity modulated proton therapy versus intensity modulated photon radiation therapy for oropharyngeal cancer: first comparative results of patient-reported outcomes. *Int J Radiol Oncol Biol Phys*. 2016;95(4):1107–1114. doi:10.1016/j.ijrobp.2016.02.044

36. Simone CB II, Plastaras JP, Jabbour SK, Lee A, Lee NY, Choi JJ, Frank SJ, Chang JY, Bradley J. Proton reirradiation: expert recommendations for reducing toxicities and offering new chances of cure in patients with challenging recurrence malignancies. *Semin Radiat Oncol*. 2020;30:253–261. doi:10.1016/j.semradonc.2020.02.007

37. Phan J, Sio TT, Nguyen TP, Takiar V, Gunn GB, Garden AS, Rosenthal DI, Fuller CD, Morrison WH, Beadle B, Ma D, Zafere ME, Hutcheson KA, Kupferman ME, William WNJ, Frank SJ. Reirradiation of head and neck cancers with proton therapy: outcomes and analyses. *Int J Radiol Oncol Biol Phys*. 2016;96:30–41. doi:10.1016/j.ijrobp.2016.03.053
38. Romesser PB, Cahlon O, Scher ED, Hug EB, Sine K, DeSelm C, Fox JL, Mah D, Garg MK, Han-Chih Chang J, Lee NY. Proton beam reirradiation for recurrent head and neck cancer: multi-institutional report on feasibility and early outcomes. *Int J Radiat Oncol Biol Phys*. 2016;95:386–395. doi:10.1016/j.ijrobp.2016.02.036

39. Janot F, de Raucourt D, Benhamou E, Ferron C, Dolivet G, Bensadoun R-J, Hamoir M, Géry B, Julieron M, Castaing M, Bardet E, Grégoire V, Bourhis J. Randomized trial of postoperative reirradiation combined with chemotherapy after salvage surgery compared with salvage surgery alone in head and neck carcinoma. *J Clin Oncol Off J Am Soc Clin Oncol*. 2008;26:5518–5523. doi:10.1200/JCO.2007.15.0102

40. Study of proton versus photon beam radiotherapy in the treatment of head and neck cancer. ClinicalTrials.gov Identifier: NCT02923570. Updated March 20, 2020. Accessed August 1, 2020. https://clinicaltrials.gov/ct2/show/NCT02923570

41. Photon therapy versus proton therapy in early tonsil cancer (ARTSCAN V). ClinicalTrials.gov identifier: NCT03829033. Updated February 28, 2020. Accessed August 1, 2020. https://clinicaltrials.gov/ct2/show/NCT03829033

42. Radiation therapy with or without chemotherapy in treating patients with high-risk malignant salivary gland tumors that have been removed by surgery. ClinicalTrials.gov identifier: NCT01220583. Updated September 4, 2018. Accessed August 1, 2020. http://clinicaltrials.gov/show/NCT01220583

43. Lee A, Kang J, Yu Y, McBride S, Riaz N, Cohen M, Sherman E, Michel L, Lee N, Tsai CJ. Trends and disparities of proton therapy use among patients with head and neck cancer: analysis from the National Cancer Database (2005-14). *Int J Part Ther*. 2019;5:1–10. doi:10.14338/IJPT-19-00051.1

44. Hutcheson KA, Lewin JS, Barringer DA, Liseck A, Gunn GB, Moore MWS, Holsinger FC. Late dysphagia after radiotherapy-based treatment of head and neck cancer. *Cancer*. 2012;118:5793–5799. doi:10.1002/cncr.27631